Barinthus Biotherapeutics Plc (BRNS)

$1.4

-0.04

(-2.71%)

Market is closed - opens 7 PM, 22 Jul 2024

Performance

  • $1.40
    $1.43
    $1.40
    downward going graph

    0.0%

    Downside

    Day's Volatility :1.75%

    Upside

    1.75%

    downward going graph
  • $1.21
    $5.10
    $1.40
    downward going graph

    13.57%

    Downside

    52 Weeks Volatility :76.27%

    Upside

    72.55%

    downward going graph

Returns

PeriodBarinthus Biotherapeutics PlcIndex (Russel 2000)
3 Months
-46.56%
0.0%
6 Months
-54.1%
0.0%
1 Year
-37.22%
0.0%
3 Years
-90.59%
-19.4%

Highlights

Market Capitalization
56.3M
Book Value
$4.41
Earnings Per Share (EPS)
-1.83
Wall Street Target Price
5.8
Profit Margin
0.0%
Operating Margin TTM
-22931.44%
Return On Assets TTM
-20.75%
Return On Equity TTM
-34.88%
Revenue TTM
334.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
44.7M
EBITDA
-74.2M
Diluted Eps TTM
-1.83
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.66
EPS Estimate Next Year
-1.74
EPS Estimate Current Quarter
-0.54
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Barinthus Biotherapeutics Plc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 314.29%

Current $1.40
Target $5.80

Technicals Summary

Sell

Neutral

Buy

Barinthus Biotherapeutics Plc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Barinthus Biotherapeutics Plc
Barinthus Biotherapeutics Plc
12.0%
-54.1%
-37.22%
-90.59%
-90.57%
Moderna, Inc.
Moderna, Inc.
-9.87%
21.5%
-2.91%
-60.58%
762.21%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
1.84%
12.81%
47.11%
81.12%
258.69%
Novo Nordisk A/s
Novo Nordisk A/s
-6.7%
24.69%
59.95%
200.63%
443.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.28%
11.69%
35.86%
150.1%
182.38%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Barinthus Biotherapeutics Plc
Barinthus Biotherapeutics Plc
NA
NA
NA
-1.66
-0.35
-0.21
NA
4.41
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.53
31.53
1.46
44.41
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.49
45.49
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.66
31.66
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Barinthus Biotherapeutics Plc
Barinthus Biotherapeutics Plc
Buy
$56.3M
-90.57%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.5B
762.21%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.5B
258.69%
31.53
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$589.9B
443.55%
45.49
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.0B
182.38%
31.66
39.46%

Insights on Barinthus Biotherapeutics Plc

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 334.0K → 5.36M (in $), with an average increase of 93.8% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -17.44M → -15.48M (in $), with an average increase of 12.7% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 59.9% return, outperforming this stock by 97.1%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 200.6% return, outperforming this stock by 291.2%

Institutional Holdings

  • M&G INVESTMENT MANAGEMENT LTD

    13.32%
  • M&G PLC

    13.32%
  • Alphabet Inc

    3.88%
  • SC China Holding Ltd

    3.64%
  • DC Funds, LP

    1.65%
  • BlueCrest Capital Management Ltd.

    1.39%

Company Information

vaccitech is a spin-out company from the university of oxford’s jenner institute, one of the oldest and most renowned vaccine research centres in the world. the company has been formed around two viral vector vaccines, one to prevent influenza and the other to treat prostate cancer. viral vector vaccines are particularly good at treating some of the most recalcitrant illnesses. the underlying technology is built on years of experience perfecting viral vector vaccine technology across multiple indications. the company’s protected chimpanzee adenovirus technology is the best way to generate t-cell responses and thereby generate lasting cell-mediated immunity. the assets are already in the clinic with very promising initial results. the founders of the company are professor adrian hill (director of the jenner institute) and professor sarah gilbert (lead in influenza and mers), who combine their exceptional scientific skills with regulatory and manufacturing experience. this autumn, vaccit

Organization
Barinthus Biotherapeutics Plc
Employees
130
CEO
Mr. William J. Enright MBA
Industry
Miscellaneous

FAQs